Beranda › Kanker Payudara Triple-Negatif › Indiana
Uji klinis Kanker Payudara Triple-Negatif di Indiana
13 studi untuk Kanker Payudara Triple-Negatif mencari peserta di lokasi di Indiana.
Kota di Indiana
Teks studi resmi (Bahasa Inggris)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- IU Simon Cancer Center, Indianapolis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06465069Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Northwest Cancer Center - Dyer Clinic ( Site 0097), Dyer
- Parkview Research Center at Parkview Regional Medical Center ( Site 0011), Fort Wayne
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06393374A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Fort Wayne Medical Oncology and Hematology ( Site 0084), Fort Wayne
- Franciscan Health ( Site 0077), Indianapolis
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06966700Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Franciscan Health Indianapolis, Indianapolis
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT05633654Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- IU Health Joe and Shelly Schwarz Cancer Center, Carmel
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT05846789Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Goshen Center for Cancer Care, Goshen
Menerima pesertaStudi observasional
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07211178A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Jul 2026 · NCT06150664A Study of LY4175408 in Participants With Advanced Cancer
- Community Health Network, Indianapolis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT07046923Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne
- Community Health Network, Inc. /ID# 243011, Indianapolis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT05005403A Study of Tetrathiomolybdate (TM) Plus Capecitabine
- Indiana University Simon Cancer Center, Indianapolis
Menerima pesertaFase 1/2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 20 Apr 2026 · NCT06134375NearWave Optical Molecular Monitoring
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Menerima peserta
Usia 18 ke atas · Wanita · Diperbarui 17 Feb 2026 · NCT06744465A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Community Health Network, Indianapolis
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Nov 2025 · NCT05902988A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- Northwest Cancer Center, Dyer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Jun 2025 · NCT06568692Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.